Literature DB >> 16174485

Fibromyalgia: present to future.

Robert Bennett1.   

Abstract

There has been a dramatic increase in our understanding of fibromyalgia throughout the past 14 years since the publication of the 1990 American College of Rheumatology classification criteria. Before 1990, and for most of the 20th century, fibromyalgia was considered to be predominantly a muscle disorder; now the critical abnormality is described as "central sensitization." However, central sensitization has to have an initial genesis and nociceptive stimuli from painful foci in muscle are increasingly recognized as being relevant to the development of fibromyalgia. Clinicians also recognize an association between the initiation of fibromyalgia and chronic psychologic stressors and inflammatory disorders. It has been more difficult to understand how two such apparently diverse events could affect central pain physiology. However, some clues are emerging from the role of diverse stimuli in activating glial cells and the role of disordered cytokine networks. Some predictions about future developments in fibromyalgia are ventured based on the current state of knowledge.

Entities:  

Mesh:

Year:  2005        PMID: 16174485     DOI: 10.1007/s11926-005-0022-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  41 in total

1.  Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits.

Authors:  Hagit Cohen; Dan Buskila; Lily Neumann; Richard P Ebstein
Journal:  Arthritis Rheum       Date:  2002-03

2.  Posttraumatic stress disorder, tenderness and fibromyalgia.

Authors:  M Amir; Z Kaplan; L Neumann; R Sharabani; N Shani; D Buskila
Journal:  J Psychosom Res       Date:  1997-06       Impact factor: 3.006

Review 3.  Treatment of cytokine-induced depression.

Authors:  Lucile Capuron; Peter Hauser; Dunja Hinze-Selch; Andrew H Miller; Pierre J Neveu
Journal:  Brain Behav Immun       Date:  2002-10       Impact factor: 7.217

4.  Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome.

Authors:  S Gürsoy; E Erdal; H Herken; E Madenci; B Alaşehirli
Journal:  Rheumatol Int       Date:  2001-10       Impact factor: 2.631

5.  COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.

Authors:  Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

6.  Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement.

Authors:  E Trysberg; H Carlsten; A Tarkowski
Journal:  Lupus       Date:  2000       Impact factor: 2.911

7.  Assessment of the hypothalamic-pituitary-adrenal axis over a 24-hour diurnal period and in response to neuroendocrine challenges in women with and without childhood sexual abuse and posttraumatic stress disorder.

Authors:  J Douglas Bremner; Meena Vythilingam; George Anderson; Eric Vermetten; Thomas McGlashan; George Heninger; Ann Rasmusson; Steven M Southwick; Dennis S Charney
Journal:  Biol Psychiatry       Date:  2003-10-01       Impact factor: 13.382

Review 8.  Evidence of involvement of central neural mechanisms in generating fibromyalgia pain.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

9.  Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.

Authors:  Savaş Gürsoy; Emin Erdal; Hasan Herken; Ercan Madenci; Belgin Alaşehirli; Nurten Erdal
Journal:  Rheumatol Int       Date:  2002-10-22       Impact factor: 2.631

10.  Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients.

Authors:  S A Jubrias; R M Bennett; G A Klug
Journal:  Arthritis Rheum       Date:  1994-06
View more
  14 in total

Review 1.  Central sensitivity syndromes: mounting pathophysiologic evidence to link fibromyalgia with other common chronic pain disorders.

Authors:  Lindsay L Kindler; Robert M Bennett; Kim D Jones
Journal:  Pain Manag Nurs       Date:  2009-12-02       Impact factor: 1.929

2.  Induction of muscle weakness by local inflammation: an experimental animal model.

Authors:  S Bicer; P J Reiser; S Ching; N Quan
Journal:  Inflamm Res       Date:  2009-04       Impact factor: 4.575

3.  Benefits of massage-myofascial release therapy on pain, anxiety, quality of sleep, depression, and quality of life in patients with fibromyalgia.

Authors:  Adelaida María Castro-Sánchez; Guillermo A Matarán-Peñarrocha; José Granero-Molina; Gabriel Aguilera-Manrique; José Manuel Quesada-Rubio; Carmen Moreno-Lorenzo
Journal:  Evid Based Complement Alternat Med       Date:  2010-12-28       Impact factor: 2.629

4.  Fibromyalgia, myofascial pain, tender points and trigger points: splitting or lumping?

Authors:  Robert M Bennett; Don L Goldenberg
Journal:  Arthritis Res Ther       Date:  2011-06-30       Impact factor: 5.156

5.  Antidepressants in the treatment of fibromyalgia.

Authors:  Chantal Moret; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

Review 6.  A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988-2005).

Authors:  Kim Dupree Jones; Dianne Adams; Kerri Winters-Stone; Carol S Burckhardt
Journal:  Health Qual Life Outcomes       Date:  2006-09-25       Impact factor: 3.186

7.  Melatonin in antinociception: its therapeutic applications.

Authors:  Venkatramanujam Srinivasan; Edward C Lauterbach; Khek Yu Ho; Dario Acuña-Castroviejo; Rahimah Zakaria; Amnon Brzezinski
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

8.  Muscle modifications in fibromyalgic patients revealed by surface electromyography (SEMG) analysis.

Authors:  Laura Bazzichi; Marco Dini; Alessandra Rossi; Silvia Corbianco; Francesca De Feo; Camillo Giacomelli; Cristina Zirafa; Claudia Ferrari; Bruno Rossi; Stefano Bombardieri
Journal:  BMC Musculoskelet Disord       Date:  2009-04-15       Impact factor: 2.362

9.  Treatment options and patient perspectives in the management of fibromyalgia: future trends.

Authors:  Kim Lawson
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Antipolymer antibody in Italian fibromyalgic patients.

Authors:  Laura Bazzichi; Camillo Giacomelli; Francesca De Feo; Tiziana Giuliano; Alessandra Rossi; Marica Doveri; Chiara Tani; Russell B Wilson; Stefano Bombardieri
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.